Inherited resistance t o activated protein C (APC), which is caused by a single point mutation in the gene for factor V, is a common risk factor for thrombosis. In this study, the prevalence of APC resistance in 18 unrelated thrombosisprone families with inherited protein S deficiency was investigated t o determine its role as additional genetic risk factor for thrombosis. In addition, a detailed evaluation of the clinical manifestations in these families was performed. Venous thrombotic events had occurred in 47% of the protein Sdeficient patients (64/136) and in 7% of relatives without protein S deficiency (14/191). As estimated from KaplanMeier analysis, 50% of protein S-deficient family members and 12% of those without protein S deficiency had had manifestation of venous thromboembolism at the age of 45 years. The age at the first thrombotic event ranged from 10 t o 81 years (mean, 32.5 years) and a large intrafamilial and ITAMIN K-DEPENDENT protein S is an important anticoagulant plasma protein that functions as that of a cofactor to activated protein C (APC) in the degradation of factors Va and VIIIa.' Hereditary deficiency of protein S is a well-established cause of familial thrombo~is.~"~ In cohorts of thrombosis patients, between 1.5% and 7% of the patients suffer from protein S deficiency.I6-" In human plasma, protein S exists in two forms, ie, as free protein S (30% to 40%) and in complex with C4b-binding Only free protein S is active as APC ~o f a~t o r .~~'~~'~ Three different types of protein S deficiency have been described': type I is characterized by a reduction in both free and total protein S,3" type I1 by a functional protein d e f e~t ?~. '~ and type I11 by a selective deficiency of free protein S.' ""' ' We have recently found type I and type I11 deficiencies to be phenotypic variants of the same genetic disease.28a APC resistance is a recently described inherited pathogenetic risk factor of venous thrornbosi~.~~~~" It is found in 21% to 60% of thrombotic patients and in 3% to 7% of healthy control^."^^^ In a majority of cases, APC resistance is caused by a single point mutation in the factor V (FV) gene, which renders FVa resistant to inactivation by APC.34-39 APC resis- 0 1995 by The American Society of Hematology. 0006-4971/95/8512-0003$3.00/0 3518 interfamilial variability in expression of thrombotic symp toms was seen. The factor V gene mutation related t o APC resistance was present in 6 (38%) of 16 probands available for testing; in total, the mutation was found in 7 (39%) of the 18 families. In family members with combined defects, 72% (13/18) had had thrombosis as compared with 19% (4/ 21) of those with only protein S deficiency and 19% (4/21) of those with only the factor V mutation. In conclusion, APC resistance was found t o be highly prevalent in thrombosisprone families with protein S deficiency and was an additional genetic risk factor for thrombosis in these families. The results suggest thrombosis-prone families with protein S deficiency often t o be affected by yet another genetic defect.
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tance has recently been found to be an additional risk factor for thrombosis in several thrombosis-prone Dutch protein Cdeficient fa mi lie^.^^,^" We have described independent inheritance of protein S deficiency and APC resistance in two families, suggesting that APC resistance may contribute to the thrombotic tendency also in protein S defi~iency.'~,~"" In contrast, in Italian families with deficiency of antithrombin 111, protein C, or protein S, no increased prevalence of APC resistance was found. 4' In this study, we describe APC resistance to be an additional genetic risk factor for thrombosis in several Swedish protein S-deficient families. In addition, we provide a detailed description of the clinical manifestations of protein S deficiency.
PATIENTS AND METHODS
Protein S-deficient families and controls. The study included 327 members from I8 unrelated families with hereditary protein S deficiency. Protein S deficiency was found in 136 (1 17 nonanticoagulated and 19 anticoagulated) relatives. A detailed description of patients and the normal and anticoagulated control populations are given in a separate report.''* Plasma levels of antithrombin 111, plasminogen, and protein C were normal in all family members (data not shown).
Laboratory methods.
Blood sampling and routine coagulation methods, including measurements of free and total protein S, were performed as described." Protein C, antithrombin 111, and plasminogen were determined with Coatest protein C, Coatest antithrombin, and Coatest plasminogen (Chromogenix, Molndal, Sweden), respectively. The APC-resistance test is a modified activated partial thromboplastin time (APTT) reaction, in which the anticoagulant response to APC is m e a~u r e d . *~.~~ Results were expressed as APC ratios (clotting time obtained using the APC/CaC12 solution divided by clotting time obtained with CaCI2). Family members with confirmed APC ratios 52.0 were considered to be APC resistant.33 Preparation of genomic DNA from EDTA blood and determination of the FV gene point mutation (G to A at position 1691), which causes APC resistance, was performed as des~ribed.~'.'~ Statistical methods. A probability less than .05 was considered significant. Laboratory data were expressed as meantstandard deviation (SD). N is the number of samples in each group. The Pearssons correlation coefficient was calculated (r). were performed with a standard x* test. Fischer's exact test was used to compare two proportions for small numbers. Thrombosisfree survival curves were constructed according to Kaplan and Meier." For comparison of two curves, the log-rank test resulting in a statistic test with a x ' distribution and one degree of freedom was ~s e d . 4~ As an approximation of the relative risk, crude odds ratios (univariate) were calculated for several putative risk factors by simple crosstabulation. These odds ratios reflect the risk when the proposed risk factor is present relative to the risk when it is absent, unadjusted for other factors. A Cox proportional hazards model was used in a multivariate survival analysis, allowing several factors to be adjusted for simultaneously. The hazard ratio is the incidence rate ratio, which is assumed to be constant over time, whereas the baseline hazard is allowed to vary.M The hazard ratio may be interpreted as the relative risk associated with each factor, adjusted for all other factors in the model. The incidence of first thrombotic events in protein S-deficient and normal relatives was calculated by counting patient-years of observation and dividing the number of events in each group by the sum of observation-years of all the individuals in the group.
RESULTS
Clinical data. Sixty-four (47%) of the 136 protein Sdeficient family members had experienced one or more venous thrombotic events as compared with 14 (7%) of the 191 relatives without protein S deficiency (Table 1) . Thrombotic episodes were associated with one or more circumstantial risk factors in 31 (48%) of the protein S-deficient patients and in 10 (71%) of the relatives without protein S deficiency ( Table 2 ). The mean age at the first thrombotic event was 32.5 years (range, 10 to 81 years) in protein S-deficient cases and 30.5 years (range, 16 to 50 years) in those without Some patients had had several risk factors provoking a thrombotic event. In addition to these circumstantial risk factors, the first thrombosis occurred after sedentary flight or car travelling in 7 protein Sdeficient patients. Values are the number of patients.
*One protein S-deficient patient had superior sagittal sinus thrombosis at age 16 in conjunction with oral contraceptives and acute media otitis.
t Two protein S-deficient patients had hormone therapy because of malignancy and two had varicosis.
protein S deficiency. According to a Kaplan-Meier analysis, the probability of a protein S-deficient family member to be free of venous thrombosis at 45 years of age was S O (95% confidence interval [CI], 0.39 to 0.61), whereas the corresponding value for family members without protein S deficiency was 0.88 (95% CI, 0.83 to 0.94; Fig 1A) . For personal use only. on December 29, 2017 . by guest www.bloodjournal.org From Protein S deficiency was a strong risk factor for thrombosis in these families (P < .001; Table 3 ). Malignancy, being overweight, and smoking appeared to be associated with increased risk of thrombosis as judged by the crude odds ratio. However, in the proportional hazard model, only being overweight was found to be a significant risk factor ( P .01). In the same model, pregnancy was not a significant risk factor of thrombosis even when only women were included in the analysis (hazard ratio, 1.5; 95% CI, 0.6 to 3.4). However, the proportional hazard model presumably underestimates pregnancy as a risk factor because the incidence of thrombosis was quite high in the years in which protein S-deficient women were pregnant (130 per 1,000 person-years). Moreover, thrombotic events occurred in 19 (13%) of 146 pregnancies in protein S-deficient women and in 6 of 163 (4%) pregnancies in women without protein S deficiency ( P < .01). In 8 of the 19 events associated with pregnancies in the protein S-deficient individuals, thrombosis occurred in the postpartum period as compared with 4 of 6 events in women without protein S deficiency. Nine (6.6%) of the 136 protein S-deficient family members (age 41 to 74 years) had had an arterial thrombotic event, compared with 3 (1.6%; age 44 to 64 years) among the 191 family members without protein S deficiency ( P < .05). When only patients older than 50 years were considered, 9 (21%) of 42 protein S-deficient relatives had had arterial thrombosis, compared with 3 (6.7%) of 45 individuals without protein S deficiency (P CC .OS). Eight of the 9 protein S-deficient patients with arterial thrombosis were smokers. In this context, it is interesting that smoking in itself lowers the plasma concentration of protein S, which may be particularly harmful in individuals with protein S defi~iency.~~ One of the 9 protein S-deficient members with arterial thrombosis was found to be heterozygous for the FV gene mutation.
Coumarine-induced skin necrosis had not occurred in any of the 55 protein S-deficient patients who had been treated with oral anticoagulant for longer or shorter periods. Moreover, no thrombotic events had occurred during adequate oral anticoagulation (warfarin) of protein S-deficient family members, even in the l1 individuals with combined APC resistance and protein S deficiency (see below). However, 4 patients had recurrences of venous thrombosis during temporary discontinuation of treatment.
APC resistance, an additionul risk factor of thrombosis. DNA samples were available from 294 family members. The Arg506 to Gln mutation in the F V gene was tested for in these 294 individuals and found to be present in 40, which included 6 (38%) of the 16 investigated probands. In family members without the FV gene mutation, APC ratios were slightly, but significantly, lower in the protein S-deficient group than in the group without protein S deficiency (Fig   2) . Among those with the FV gene mutation, there was no difference in APC ratios between those with and without protein S deficiency. When all 18 families (294 members) were included in analysis of phenotypic expression, a significant difference in thrombotic frequency ( P = .041) but not in thrombosis-free survival ( P = ,090) was found between family members with only protein S deficiency and those with combined defects (Table 4A) . To evaluate the influence of the FV gene mutation more stringently, only the 7 families having both defects (families 2, 6, 8, 10, I I , 12, and 18)28a were included in the analysis. Individuals with combined defects were found to have significantly higher incidence of thrombosis than family members with either of the two defects ( P = .W]), the differences being significant even after exclusion of probands from the analysis ( P = .034 and P = .028, respectively; Table 4B ). In these families, the mean age at the first thrombotic episode was 3 I years for subjects having both defects (n = 13; range, 10 to S5 years), 47 years for subjects with only protein S deficiency (n = 4; range, 30 to 65 years), and 27 years for those with only the FV gene mutation (n = 4; range, 21 to 31 years). The thrombosis-free survival curve of individuals with both defects was significantly different from those of individuals with either protein S deficiency or the FV gene mutation (Fig 3) . There was no significant difference between those with only the FV gene mutation and those with isolated protein S deficiency. Noteworthy, three family members were homozygous for the FV gene mutation, 2 with normal protein S being asymptomatic (ages 14 and 8 years, respectively) and l with protein S deficiency having had thrombosis at 10 years of age.
DISCUSSION
Deficiency of protein S is a strong risk factor of thrombosis and 64 of the 136 protein S-deficient relatives had experienced one or more venous thrombotic events. The incidence of first thrombotic event increased with age, showing protein S deficiency to be a life-long risk factor of thrombosis. The clinical manifestations of protein S deficiency in this study were similar to those described in an earlier report, in which For personal use only. on December 29, 2017 . by guest www.bloodjournal.org From 
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only total protein S was measured." However, in the now described families, the median age for the first thrombosis was 45 years (50 years if probands were excluded), as compared with less than 30 years in the cited study. This finding is not explained by the different detection methods for protein S deficiency (measurements of free v total protein S ) because we found no significant difference in thrombosisfree survival between patients with so called type I and those with type 111 deficiency. The age at the first thrombotic event ranged between 10 and 81 years and one patient was still asymptomatic at 7 6 years of age. This is a wider range than found in a previous study (range, 15 to 68 years)." It is becoming evident that thrombosis-prone families with protein C deficiency often have more than one genetic defect (see below). In the general population, approximately 1 in 250 carry protein C deficiency'" and the risk of thrombosis in individuals with isolated protein C deficiency
is not yet determined. In a recent report on thrombosis-prone families with protein C deficiency, the probability of being free of thrombosis was found to be 50% at 45 years of age" and the results of this report suggest the risk of thrombosis in thrombosis-prone families with protein S deficiency to be similar. The higher thrombosis risk in previous studies with protein S deficiency may be caused by the selection of severely affected families. Epidemiologic studies are needed to elucidate the prevalence of protein S deficiency in the general population and to determine the associated risk of thrombosis.
The expression of clinical manifestations in protein Sdeficient members showed a marked interfamilial and intrafamilial heterogeneity and the thrombotic tendency in relatives without protein S deficiency was higher than expected. This finding suggests additional genetic risk factors to be One such genetic factor is the FV gene mutation causing APC resistance, which was found in 7 of the 18 protein S-deficient families.
In these families, individuals with combined protein S deficiency and APC resistance had a higher risk for thrombosis than those carrying either of the two defects. APC resistance was recently found to be an additional risk factor for thrombosis in Dutch families with protein C deficiency,m whereas no cases of APC resistance were found in Italian families with protein S, protein C, or antithrombin I11 deficiency:' This difference may be caused by higher allele frequencies of the FV Gln506 mutation in the Dutch and Swedish populations than in the Italian population.
In the families with combined defects, only 19% (4/21) of the individuals with only protein S deficiency and 19% (4/21) of those with only the FV gene mutation had had thrombosis. Thus, in these families there was no difference in severity of the thrombotic disease between individuals with only protein S deficiency and those with only FV gene mutation. In contrast, 72% (13/18) of those with combined defects had suffered from thrombosis. In this context it is noteworthy that there was no significant difference in thrombosis-free survival between relatives with isolated protein S deficiency and combined defects when all 18 families were considered. This finding would tend to suggest that many of the thrombosis-prone protein S-deficient families without the FV gene mutation have other genetic defects. This is illustrated by a high incidence of thrombosis in family no. l*'" in which 23 of 41 protein S-deficient and 6 of 8 1 nondeficient relatives had had venous thrombosis, with the age of onset of thrombosis ranging between 1 1 and 71 years of age. A large variability in clinical symptoms of protein S-deficient members was also observed in the other 10 families without APC resistance (3 of 39 nondeficient relatives and 22 of 47 protein S-deficient relatives having had venous thrombosis; the age range of first thrombosis in protein S-deficient cases was 13 to 66 years), which supports the idea that multiple genetic defects cause thrombophilia. The variability in expression of symptoms may also be related to the nature of the causative mutation. Thus, different mutations may be associated with different risks of thrombosis even if they have the same protein S concentration. Circumstantial risk factors also affect expression of thrombotic manifestations, as shown by the observation that 48% of first thrombotic events occurred in conjunction with circumstantial risk factors such as pregnancy, trauma, surgery, or oral contraceptives.
In conclusion, although hereditary protein S deficiency is associated with a life-long increased risk of venous thrombosis, expression of clinical manifestations varies between different families depending on whether additional genetic and circumstantial risk factors are present or not. APC resistance, which is highly prevalent in the general population, was found to be an additional risk factor for thrombosis in several thrombosis-prone protein S-deficient families.
